Growth Metrics

Travere Therapeutics (TVTX) Cash from Investing Activities (2016 - 2025)

Travere Therapeutics' Cash from Investing Activities history spans 13 years, with the latest figure at -$104.8 million for Q4 2025.

  • For Q4 2025, Cash from Investing Activities fell 30.54% year-over-year to -$104.8 million; the TTM value through Dec 2025 reached $27.9 million, down 71.92%, while the annual FY2025 figure was $27.9 million, 71.92% down from the prior year.
  • Cash from Investing Activities reached -$104.8 million in Q4 2025 per TVTX's latest filing, down from $86.6 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $104.9 million in Q1 2024 to a low of -$105.7 million in Q1 2021.
  • Average Cash from Investing Activities over 5 years is -$9.7 million, with a median of -$6.7 million recorded in 2023.
  • Peak YoY movement for Cash from Investing Activities: plummeted 822.85% in 2023, then skyrocketed 383.21% in 2024.
  • A 5-year view of Cash from Investing Activities shows it stood at $7.4 million in 2021, then crashed by 597.98% to -$36.7 million in 2022, then soared by 50.47% to -$18.2 million in 2023, then crashed by 341.79% to -$80.3 million in 2024, then crashed by 30.54% to -$104.8 million in 2025.
  • Per Business Quant, the three most recent readings for TVTX's Cash from Investing Activities are -$104.8 million (Q4 2025), $86.6 million (Q3 2025), and $4.8 million (Q2 2025).